FY2026 EPS Estimates for QNRX Decreased by Zacks Research

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) – Stock analysts at Zacks Research reduced their FY2026 earnings estimates for shares of Quoin Pharmaceuticals in a research note issued on Thursday, August 27th. Zacks Research analyst M. Marin now expects that the company will earn ($7.45) per share for the year, down from their prior estimate of ($7.38). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($7.38) per share.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29).

QNRX has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, July 20th. ThinkEquity assumed coverage on Quoin Pharmaceuticals in a research report on Monday, June 15th. They set a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold”.

Quoin Pharmaceuticals Price Performance

Shares of QNRX stock opened at $6.51 on Wednesday. The company’s fifty day moving average price is $4.77 and its two-hundred day moving average price is $5.89. The firm has a market capitalization of $13.09 million, a P/E ratio of -0.26 and a beta of 1.50. Quoin Pharmaceuticals has a 12 month low of $3.25 and a 12 month high of $41.80.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Ikarian Capital LLC bought a new stake in shares of Quoin Pharmaceuticals during the fourth quarter valued at about $3,052,000. Millennium Management LLC bought a new position in Quoin Pharmaceuticals in the 4th quarter valued at about $1,080,000. SummitTX Capital L.P. acquired a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $935,000. Boothbay Fund Management LLC acquired a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $863,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Quoin Pharmaceuticals during the 4th quarter worth about $840,000. 8.63% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Quoin Pharmaceuticals news, CEO Michael Myers purchased 20,490 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were bought at an average price of $4.88 per share, with a total value of $99,991.20. Following the completion of the acquisition, the chief executive officer owned 37,713 shares in the company, valued at approximately $184,039.44. This represents a 118.97% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anthony James Culverwell acquired 6,146 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $4.88 per share, with a total value of $29,992.48. Following the completion of the transaction, the director owned 40,364 shares of the company’s stock, valued at approximately $196,976.32. This trade represents a 17.96% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 57,370 shares of company stock worth $279,966 over the last ninety days. 11.17% of the stock is owned by company insiders.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.